期刊文献+

体外膜肺氧合中的凝血系统异常及其解决方法 被引量:1

下载PDF
导出
摘要 体外膜肺氧合(extracorporeal membrane oxygenation,ECMO)是用于暂时部分替代心肺功能的一种技术,目前已成功地应用于各种呼吸和循环障碍的支持。然而,在其应用过程中仍然存在着许多并发症,其中凝血系统障碍目前仍是ECMO最常见的并发症之一,这也是终止ECMO治疗的常见原因。ECMO治疗过程中往往存在着多种凝血因子的激活消耗,故凝血系统紊乱在ECMO中经常发生。而由于人造表面等原因导致血小板消耗,使出血在EC.MO治疗中亦屡见不鲜。如何降低ECMO过程中凝血系统功能障碍的发生率,降低此类并发症的危害,已成为ECMO治疗的研究热点之一。
作者 李伯君 李彤
出处 《天津医科大学学报》 2008年第3期405-408,共4页 Journal of Tianjin Medical University
  • 相关文献

参考文献27

  • 1Gil W.Infiammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation [J].Perfusion, 2001,16( 1 ):27
  • 2Arnold P, Jackson S, Wallis J, et al.Coagulation factor activity duringneonatal extra-corporeal membrane oxygenation [J].Intensive Care Med, 2001,27 (8):1395
  • 3Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation[J]. Artif Organs, 1999,23 ( 11 ) :979
  • 4陈扬,陆铸今,吴王月.体外膜肺中的止血与凝血功能异常及其干预措施[J].国外医学(儿科学分册),2005,32(4):193-196. 被引量:3
  • 5金秀国,方国安,刘波,刘晓光,庄晓玲,方汉波.体外循环对血小板功能的影响[J].临床检验杂志,2005,23(4):298-299. 被引量:8
  • 6Cheung PY, Sawicki G,Salas E, et al.The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates[J].Crit Care Med,2000,28 (7) :2584
  • 7隋波,李茂源,谢厚云,马玉恒,孙潮涌,田雷,王维.心肺转流对小儿血小板膜糖蛋白的影响[J].中国当代儿科杂志,2006,8(3):247-248. 被引量:1
  • 8吕俊海,刘明东,韩颖.血小板保存损伤的研究进展[J].中国输血杂志,2002,15(1):65-67. 被引量:21
  • 9Baird CW, Zurakowski D,Robinson B, et al.Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival[J]. Ann Thorac Surg, 2007, 83(3):912
  • 10Nankervis CA, Preston TJ,Dysart KC, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation[J]. ASAIO J, 2007,53 ( 1 ): 111

二级参考文献61

  • 1Cheung PY, Sawicki G, Salas E, et al. The mechanisms of platelet dysfunction during extracorporeal membrane oxygenation in critically ill neonates[J ].Pediatric Crit Care Med,2000,28(7):2584-2589.
  • 2Ereth MH, Nuttall GA, Ericson DG, et al. Platelet glass bead retention predicts bleeding after cardiac surgery [ J ]. J Cardiothorac Vasc Anesth,2001,15(1) :49-54.
  • 3Plotz F. Extracorporeal membrane oxygenation and clotting revisited [ J ]. J Pediatr, 1997,130(5) :847-848.
  • 4Cook KE, Maxhimer J, Leonard DJ, et al. Platelet and leukocyte activation and design consequences for thoracic artificial lungs[J]. ASAIO J,2002,48(6): 620-630.
  • 5Sawickl G, Salas E, Murat J, et al. Release of gelatinase A during platelet activation mediates aggregation[J]. Nature, 1997,386(6625) :616-619.
  • 6Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation[J]. Artif Organs, 1999,23( 11 ) :979-983.
  • 7Gil W. Inflammo-coagulatory response,extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation [ J ]. Perfusion,2001,16(1 ) :27-35.
  • 8Urlesberger B, Zobel G, Zenz W, et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants[J]. J Pediatr, 1996,129(2) :264-268.
  • 9Arnold P, Jackson S, Wallis J, et sl. Coagulation factor activity during neonatal extracorporeal membrane oxygenation [ J ]. Intensive Care Med,2001,27(8): 1395-1400.
  • 10Kawada T, Kitagawa H, Hoson M, et al. Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation[J]. Hematol Oncol Clin North Am,2000,14(2) :445-457.

共引文献29

同被引文献7

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部